Zacks Research Analysts Raise Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Equities researchers at Zacks Research boosted their Q1 2026 earnings per share (EPS) estimates for Axsome Therapeutics in a report issued on Monday, October 27th. Zacks Research analyst Team now forecasts that the company will post earnings per share of ($0.60) for the quarter, up from their previous forecast of ($0.64). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.79) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q2 2026 earnings at ($0.51) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at $0.03 EPS, FY2026 earnings at ($1.17) EPS, Q1 2027 earnings at $1.10 EPS, Q3 2027 earnings at $1.25 EPS and FY2027 earnings at $4.12 EPS.

Other research analysts have also recently issued research reports about the stock. Morgan Stanley lifted their price target on shares of Axsome Therapeutics from $191.00 to $194.00 and gave the stock an “overweight” rating in a research note on Monday, October 20th. Needham & Company LLC reiterated a “buy” rating and set a $150.00 price target on shares of Axsome Therapeutics in a research note on Monday, August 4th. B. Riley started coverage on Axsome Therapeutics in a research report on Wednesday, October 1st. They set a “buy” rating and a $179.00 target price on the stock. Royal Bank Of Canada lifted their target price on Axsome Therapeutics from $184.00 to $189.00 and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Finally, Wells Fargo & Company upgraded Axsome Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 3rd. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Axsome Therapeutics presently has a consensus rating of “Buy” and an average price target of $178.20.

Axsome Therapeutics Trading Down 0.1%

Shares of NASDAQ:AXSM opened at $133.15 on Thursday. The stock has a market capitalization of $6.64 billion, a price-to-earnings ratio of -26.26 and a beta of 0.52. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.51 and a current ratio of 1.57. The stock’s 50-day simple moving average is $122.75 and its two-hundred day simple moving average is $112.26. Axsome Therapeutics has a 52-week low of $75.56 and a 52-week high of $139.13.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, August 4th. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.00) by $0.08. Axsome Therapeutics had a negative return on equity of 283.22% and a negative net margin of 49.88%.The company had revenue of $150.04 million for the quarter, compared to analysts’ expectations of $140.02 million.

Institutional Trading of Axsome Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Emerald Mutual Fund Advisers Trust increased its stake in Axsome Therapeutics by 2.5% in the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 65,505 shares of the company’s stock worth $7,956,000 after buying an additional 1,570 shares during the period. Covestor Ltd increased its stake in Axsome Therapeutics by 294.5% in the 3rd quarter. Covestor Ltd now owns 501 shares of the company’s stock worth $61,000 after buying an additional 374 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Axsome Therapeutics by 30.7% during the third quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 67,902 shares of the company’s stock worth $8,247,000 after acquiring an additional 15,934 shares during the period. Wealth Enhancement Advisory Services LLC increased its position in shares of Axsome Therapeutics by 4.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 21,505 shares of the company’s stock worth $2,551,000 after acquiring an additional 827 shares during the period. Finally, Fiduciary Family Office LLC purchased a new position in shares of Axsome Therapeutics during the third quarter worth approximately $324,000. Hedge funds and other institutional investors own 81.49% of the company’s stock.

Insider Buying and Selling at Axsome Therapeutics

In other news, COO Mark L. Jacobson sold 10,000 shares of the stock in a transaction on Monday, September 22nd. The shares were sold at an average price of $115.96, for a total value of $1,159,600.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Mark Coleman acquired 1,575 shares of Axsome Therapeutics stock in a transaction that occurred on Monday, September 8th. The stock was purchased at an average cost of $127.28 per share, for a total transaction of $200,466.00. Following the completion of the transaction, the director directly owned 48,212 shares in the company, valued at $6,136,423.36. This trade represents a 3.38% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold a total of 243,332 shares of company stock valued at $28,824,746 over the last quarter. 22.30% of the stock is owned by corporate insiders.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.